746 related articles for article (PubMed ID: 11059695)
21. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect.
Penafuerte C; Galipeau J
Cancer Immunol Immunother; 2008 Aug; 57(8):1197-206. PubMed ID: 18214474
[TBL] [Abstract][Full Text] [Related]
22. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
Cao X; Wang Q; Ju DW; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
[TBL] [Abstract][Full Text] [Related]
23. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
Mazorra Z; Mesa C; Fernández A; Fernández LE
Cancer Immunol Immunother; 2008 Dec; 57(12):1771-80. PubMed ID: 18351335
[TBL] [Abstract][Full Text] [Related]
24. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
25. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D
Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572
[TBL] [Abstract][Full Text] [Related]
27. [Anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Wei Y; Kan B
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):118-21. PubMed ID: 11783014
[TBL] [Abstract][Full Text] [Related]
28. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice.
Kircheis R; Küpcü Z; Wallner G; Rössler V; Schweighoffer T; Wagner E
Cancer Gene Ther; 2000 Jun; 7(6):870-8. PubMed ID: 10880017
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.
Ribas A; Amarnani SN; Buga GM; Butterfield LH; Dissette VB; McBride WH; Glaspy JA; Ignarro LJ; Economou JS
Cancer Gene Ther; 2002 Nov; 9(11):875-83. PubMed ID: 12386826
[TBL] [Abstract][Full Text] [Related]
31. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
32. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
[TBL] [Abstract][Full Text] [Related]
33. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
[TBL] [Abstract][Full Text] [Related]
34. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
Yang Y; Yang S; Ye Z; Jaffar J; Zhou Y; Cutter E; Lieber A; Hellström I; Hellström KE
Cancer Res; 2007 Mar; 67(5):2339-44. PubMed ID: 17332366
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism.
Steitz J; Brück J; Knop J; Tüting T
Gene Ther; 2001 Aug; 8(16):1255-63. PubMed ID: 11509959
[TBL] [Abstract][Full Text] [Related]
36. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
37. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
[TBL] [Abstract][Full Text] [Related]
38. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
39. Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation.
Zhang J; Wang Q; Zhao D; Cao X
Cytotherapy; 2007; 9(4):386-96. PubMed ID: 17573614
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
